The annual meeting of the American Society of Clinical Oncology (twitter hashtag #ASCO13) is fast approaching. Later this week over 30,000 attendees will head to Chicago to hear the latest data on new cancer drugs and the results of clinical trials.
The expected highlight of the ASCO 2013 meeting will be data on PD-1 and PD-L1 immunotherapies: nivolumab (BMS), MPDL3280A (Roche) and lambrolizumab (Merck).
As Sally Church, PhD notes in her ASCO 2013 PD-1 PD-L1 highlights post on Pharma Strategy Blog when considering these new immunotherapies, important questions need to be answered:
- How much of a prolonged effect with PD-1/PD-L1 immunotherapies have over 5 years?
- What will be their effect on subsequent therapies?
- Will they boost or hinder sequencing and in which tumour types?
- Is there a biomarker of response?
- Is a diagnostic necessary?
Sally says “it continues to be an exciting area of oncology” and she’s “really looking to the presentations on PD-1/PD-L1.” We expect this to be the data of the meeting.
Another hot topic with a lot happening at ASCO 2013 is Chronic Lymphocytic Leukemia (CLL). Earlier this year the FDA granted it’s new Breakthrough designation to two drugs in development with CLL indications: ibrutinib from Pharmacyclics and obinutuzumab (GA101) from Roche/Genentech.
Other CLL new drugs with data at ASCO 2013 include idelalisib (GS-1101) from Gilead, IPI-145 from Infinity and ABT-199 being developed by Abbvie & Genentech. A cloud hangs over ABT-199 after the death of 2 CLL patients due to tumor lysis syndrome and this is likely to be a topic of discussion at ASCO. You can read more about the companies in the race to market in CLL on Biotech Strategy Blog.
Finally, you can now watch Sally Church’s video preview of what’s hot at ASCO 2013, it’s available for free, but you do have to sign-up on Pharma Strategy Reports to obtain the access link and password. Check it out!